• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Edgewise Therapeutics, Inc. - Common Stock (NQ:EWTX)

29.31 -0.20 (-0.68%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 627,581
Open 29.60
Bid (Size) 27.28 (100)
Ask (Size) 31.00 (500)
Prev. Close 29.51
Today's Range 28.19 - 29.61
52wk Range 10.60 - 31.29
Shares Outstanding 105,341,296
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
ORBIMED Advisors Trims $125 Million Terns Stake After a Breakout Year, According to SEC Filing ↗
February 20, 2026
Terns Pharmaceuticals has delivered a significant rally over the past year, lifting expectations around its clinical pipeline. The latest filing shifts attention to upcoming data and the company’s... 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Xenon Stock at $42: What to Know of a $75 Million Trim Ahead of March Phase 3 Data ↗
February 19, 2026
This biotech specializes in clinical-stage therapies for neurological disorders, with a pipeline targeting epilepsy and related conditions. 
Via The Motley Fool
Topics Regulatory Compliance

Performance

YTD
+23.4%
+23.4%
1 Month
-1.6%
-1.6%
3 Month
+24.8%
+24.8%
6 Month
+105.0%
+105.0%
1 Year
+8.3%
+8.3%

More News

Read More
News headline image
Inside a $58 Million Bet on Kodiak Amid $184 Million Offering and Phase 3 Readouts Ahead ↗
February 19, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Fund Just Disclosed a New $55 Million Bet on Centessa Amid 53% Stock Rally and CEO Transition ↗
February 19, 2026
Via The Motley Fool
News headline image
CG Oncology Soars 102% in a Year, but One Investor Just Disclosed a $58.5 Million Sale ↗
February 19, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
BrightSpring Stock Up 86% as Braidwell Takes $45 Million Stake in Healthcare Services Provider ↗
February 19, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
MoonLake Stock Soars As Biotech Fund Reloads, Takeover Chatter Ignites ↗
February 17, 2026
Via Stocktwits
News headline image
Why Edgewise Therapeutics Stock Crushed the Market on Monday ↗
February 09, 2026
Via The Motley Fool
News headline image
This Biotech Fund Exited an $8 Million Edgewise Stake as the Stock Slid Double Digits ↗
December 29, 2025
Via The Motley Fool
News headline image
Why Edgewise Therapeutics Stock Rocked the Market Today ↗
December 24, 2025
Via The Motley Fool
News headline image
Let's take a look at the stocks that are in motion in today's session. ↗
December 24, 2025
Via Chartmill
News headline image
Edgewise Therapeutics Stock Jumps After Trial Update For Genetic Heart Disease — Wall Street Eyes A Potential Standout ↗
December 24, 2025
Via Stocktwits
News headline image
Capricor Therapeutics (NASDAQ: CAPR) Soars 535% to Eight-Year High on Landmark Duchenne Muscular Dystrophy Treatment Results
December 03, 2025
Via MarketMinute
News headline image
This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestones ↗
December 03, 2025
Via The Motley Fool
Topics Initial Public Offering Regulatory Compliance
News headline image
Biotech Fund Reveals $15 Million MoonLake Exit After Stock’s 90% Crash ↗
November 28, 2025
Via The Motley Fool
Topics Lawsuit Regulatory Compliance
News headline image
Biotech Fund Reveals $15 Million MoonLake Exit After Stock’s 90% Crash ↗
November 27, 2025
Via The Motley Fool
Topics Lawsuit Regulatory Compliance
News headline image
This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestones ↗
November 27, 2025
Via The Motley Fool
Topics Initial Public Offering Regulatory Compliance
News headline image
Biotech Fund Dumps $12.3 Million in Crinetics Stock as Shares Remain 19% Lower on the Year ↗
November 27, 2025
Via The Motley Fool
Topics Regulatory Compliance
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX
August 17, 2025
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX
August 13, 2025
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX
August 09, 2025
From Pomerantz LLP
Via GlobeNewswire
News headline image
Edgewise Therapeutics Inc (NASDAQ:EWTX) Q2 2025 Earnings: EPS Beat Sparks 5% Pre-Market Rally ↗
August 07, 2025
Via Chartmill
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX
August 05, 2025
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX
August 01, 2025
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX
July 28, 2025
From Pomerantz LLP
Via GlobeNewswire

Frequently Asked Questions

Is Edgewise Therapeutics, Inc. - Common Stock publicly traded?
Yes, Edgewise Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Edgewise Therapeutics, Inc. - Common Stock trade on?
Edgewise Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Edgewise Therapeutics, Inc. - Common Stock?
The ticker symbol for Edgewise Therapeutics, Inc. - Common Stock is EWTX on the Nasdaq Stock Market
What is the current price of Edgewise Therapeutics, Inc. - Common Stock?
The current price of Edgewise Therapeutics, Inc. - Common Stock is 29.31
When was Edgewise Therapeutics, Inc. - Common Stock last traded?
The last trade of Edgewise Therapeutics, Inc. - Common Stock was at 02/20/26 04:00 PM ET
What is the market capitalization of Edgewise Therapeutics, Inc. - Common Stock?
The market capitalization of Edgewise Therapeutics, Inc. - Common Stock is 3.09B
How many shares of Edgewise Therapeutics, Inc. - Common Stock are outstanding?
Edgewise Therapeutics, Inc. - Common Stock has 3B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap